Blood Impact Factor

Blood's IF is unusually high for a specialty journal. Most single-disease or single-organ journals sit in the 5-15 range. Blood's 23.1 reflects two things: the journal publishes across the entire breadth of hematology (basic, clinical, translational), and hematology as a field has high citation density because blood disease research feeds directly into treatment changes.

The five-year JIF (19.7) running slightly below the two-year (23.1) suggests that Blood papers get cited heavily in the first two years after publication, which is characteristic of clinical research that gets incorporated into practice quickly. This is different from basic biology journals where citation peaks later.

For career purposes, a Blood publication is universally recognized in hematology. It carries weight with grant panels, hiring committees, and promotion reviewers. The journal's ASH affiliation means it's the default prestige target for hematologists worldwide.

The decline from 25.5 (2021) to 23.1 (2024) looks concerning on paper but reflects the broader post-pandemic normalization. COVID-era hematology research (coagulation in COVID, immune responses, vaccine effects on blood) inflated citations in 2020-2021. The current 23.1 is likely Blood's structural baseline, which is still excellent for a specialty journal.

In our pre-submission review work on manuscripts targeting Blood, three submission patterns account for most of the desk rejections we see.

Hematology-adjacent submissions that are actually immunology or oncology. The most common error we see is authors submitting papers where blood cells are the experimental system but the scientific question belongs to another field. A paper asking how a transcription factor regulates myeloid differentiation is a hematology paper. A paper using neutrophils as a convenient cell type to study a general signaling pathway is not. Blood editors read the framing carefully: if the paper would still make sense submitted to Immunity or Cancer Cell with minor changes, it is not a Blood paper. The hematology logic has to be the organizing principle, not a convenience or a late-stage reframe.

Small clinical series without practice implications. Clinical hematology submissions that describe a cohort of patients without a clear management takeaway get redirected to Blood Advances or disease-specific journals. What Blood wants is clinical evidence that changes how hematologists think about a treatment decision, not case accumulation. We see this pattern frequently with rare disease subgroups and novel biomarker reports: the data is real but there is no clear "this changes how I would manage the next patient" argument. If you cannot articulate that argument in one sentence, the editors will struggle to place the paper.

Basic biology that mentions blood cells but never engages with blood disease. A mechanistic paper in blood cell biology that never addresses disease relevance will face heavy scrutiny at Blood, which sits at the intersection of basic and clinical hematology. We see manuscripts that generate technically strong molecular data in HSCs or platelets but frame everything in terms of basic biology without connecting to the pathophysiology that Blood's readership would care about. The connection does not have to be direct or translational in a clinical sense, but the reader has to understand why this mechanism matters for understanding blood disease, not just cell biology in general.

A Blood submission readiness check can identify whether your manuscript's framing aligns with Blood's editorial expectations before you commit to a full submission.

Blood's editors want papers that the hematology community will use. That sounds obvious, but it means different things for different paper types:

For basic hematology: The mechanism must connect to blood cell biology or blood disease. A paper about a transcription factor that happens to be expressed in blood cells isn't automatically Blood material. The hematology has to be the point, not the model system.

For clinical hematology: The evidence needs to change or inform clinical practice. A small case series without a clear management implication usually gets redirected. The editors want papers that practicing hematologists will cite when making treatment decisions.

For translational work: The bench-to-bedside bridge needs to be visible. Animal model data is fine, but the path to human relevance should be plausible, not speculative.

Submit if:

• the finding advances hematology in a way that the community will build on or use clinically
• the paper covers any area of blood biology or blood disease (the scope is intentionally broad)
• the evidence quality matches the claim (rigorous methodology, appropriate statistics)
• you want the ASH flagship's audience and credibility

Think twice if:

• the hematology connection is incidental (the paper is really immunology, oncology, or biochemistry)
• Blood Advances would reach the same audience with a faster, less competitive review
• Leukemia or another disease-specific journal would give better visibility for the specific topic
• the finding is incremental for hematology even if technically sound

A Blood submission readiness check can help assess whether the hematology framing and evidence strength meet Blood's editorial expectations.

Blood is the kind of journal where authors can confuse brand strength with fit. The page is only useful if it helps the searcher answer the real submission question: will this paper matter to the broader hematology community, or is it actually a narrower leukemia, thrombosis, transplant, oncology, or immunology story that happens to involve blood? That is the decision Blood editors are making long before the paper reaches review.

The number helps because it confirms Blood is still a top hematology venue with real field authority. But the better filter is community consequence. A manuscript belongs here when hematologists outside the immediate niche would still recognize the result as important to how blood disease, blood cell biology, or patient management is understood. If the paper needs a lot of specialty framing to justify itself, the impact factor is not the decisive argument.

The post-pandemic decline from earlier peaks matters less than authors often think. Blood's current number still reflects a journal with unusually strong citation density for a specialist society title, and the ASH ecosystem gives the journal a kind of field reach that the raw JIF only partially captures. That is especially important for authors deciding between Blood, Leukemia, Haematologica, or Blood Advances. Blood is not just a higher number. It is a broader hematology stage with a higher editorial bar for community relevance.

• It helps when the manuscript clearly changes a hematology decision, mechanism, or practice conversation.
• It helps when the audience is the wider hematology field rather than a narrow disease slice alone.
• It misleads when the story is really oncology, immunology, or cell biology with only a peripheral hematology frame.
• It misleads when authors use the prestige of Blood to avoid asking whether Blood Advances or a narrower hematology journal is the more honest fit.

• Blood submission guide
• Blood submission process
• Blood review time
• How to avoid desk rejection at Blood
• Is Blood a good journal?